首页>投融资
瑞博生物
E~PreIPO
瑞博生物是一家致力于开发小核酸药物的创新型药物研发企业。公司自主开发并建立了涵盖小核酸药物从早期研发到产业化的整个生命周期的全技术链整合的小核酸药物研发平台，包括小核酸序列设计及高通量筛选平台、小核酸药物递送技术平台、小核酸稳定化修饰平台、小核酸药物生物分析平台、小核酸药学研究平台、小核酸单体研发平台等六大核心技术平台。
基本信息
-
公司全称苏州瑞博生物技术股份有限公司
-
类型siRNA药物开发商
-
产业领域药品研发/制造、医药研发/制造、生物药、化学药
-
公司人数101~500人
-
地址江苏省昆山市玉山镇元丰路168号
-
联系电话
-
邮箱lvc@ribolia.com
-
成立时间2007-01-17
投融资
-
2024-09-26E~PreIPO2000万人民币磐霖资本
-
2022-07-29E轮4000万美元三一创新投资磐霖资本
-
2022-07-29E~PreIPO4000万美元磐霖资本君联资本三一创新投资
-
2020-09-30C轮3.11亿人民币国投创新蓝海资本朗玛峰创投深圳众汇投资中国国新基金磐霖资本昆山创投弘陶资本启融创投正和元通资本君联资本昆山高新创投泽鸿生物昆山瀚漾投资大榭允公投资恒旭资本上海蓝石投资昆山市工研院创投上海自贸区基金三一创新投资高瓴资本
-
2020-04-03C轮4.7亿人民币朗玛峰创投深圳众汇投资国药中金弘陶资本恒旭资本高瓴资本中金启德基金中国国有资本风险投资基金上海自贸区基金
-
2019-12-05C轮2.03亿人民币深圳众汇投资蓝海资本创源垣投资三一创新投资国投创新瀚漾资本磐霖资本君联资本大榭允公投资
-
2017-03-17B轮2.7亿人民币荷塘创投GGV纪源资本国投创新磐霖资本君联资本正和元通资本
-
2015-09-28A轮1.25亿人民币GGV纪源资本昆山小核酸研究所联想之星磐霖资本君联资本
- 加载更多
相关投融资企业
收并购
Advanced Accelerator Applications (AAA), a subsidiary of Novartis AG, founded in 2002 by Italian academics as a spin-off from the European Organization for Nuclear Research (CERN, Switzerland), develops diagnostic and therapeutic products, including PET radiopharmaceuticals. The company focuses on Personalized Medicine, aimed at providing treatments tailored to a patient's profile and disease, using predictive, preventive and personalized procedures. In January 2018, AAA became a subsidiary of Novartis AG.In July 2016, the company opened its first US manufacturing facility in Millburn, NJ. The Millburn plant served as a distribution center for NETSPOT.In April 2014, AAA opened a new office in the US located at Manhattan, NY. At that time, the company planned to set up a new manufacturing facility in the US.In February 2012, AAA planned to build a radiopharmaceutical facility in Murcia, Spain. The facility was expected to be completed within 18 months.By December 201
B轮
Veradermics Inc (美国)：Veradermics是一家位于美国的生物技术公司，专注于皮肤健康和美容产品的研发。公司的主要研究领域包括皮肤再生、抗衰老和皮肤修复。Veradermics利用其专有的生物材料和技术平台，开发了一系列高效的皮肤护理产品。公司的产品线包括抗衰老面霜、皮肤修复凝胶和皮肤再生面膜等。
B轮
Qnovia, formerly known as Respira Technologies, is focused on developing inhaled drug delivery platforms to deliver drugs for nicotine replacement therapy and cardiopulmonary diseases.In September 2022, the company changed its name from Respira Technologies to Qnovia.In September 2022, the company raised USD 17M in Series A funding led by Blue Ledge Capital, DG Ventures, Evolution VC Partners, Gaingels, TL Capital, and Vice Ventures,
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息